Literature DB >> 23749925

18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.

Jiri Ferda1, Eva Ferdova, Milan Hora, Ondrej Hes, Jindrich Finek, Ondrej Topolcan, Boris Kreuzberg.   

Abstract

AIM: to assess the influence of positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose ((18)F-FDG-PET/CT) on the treatment decision in renal cell carcinoma and to assess the prognostic value of the (18)F-FDG accumulation assessments. PATIENTS AND METHODS: Data from 60 patients were included. The cohort consisted of 43 males, 17 females, mean age 66.2 years (range=49-86 years). All patients underwent (18)F-FDG-PET/CT including two-phase CT-angiography of the kidneys. Locally advanced or generalized renal cell carcinoma was suspected in all patients. The level of the (18)F-FDG accumulation within the tumor was compared with the histological grading and the development of the disease was assessed 12 months after (18)F-FDG-PET/CT.
RESULTS: Overall mortality reached 46.7%, the highest (18)F-FDG accumulation showed tumor of grade 4 (mean SUV(max)=10.7, range=5-23), the highest mortality was found for tumors exceeding SUV(max) value of 10 (mortality 62.5%). New information was brought by (18)F-FDG-PET/CT in 85% of cases.
CONCLUSION: (18)F-FDG-PET/CT has the potential to estimate the patient's survival according to the (18)F-FDG accumulation measured in SUV(max). Depiction of occult metastatic disease has an emerging role in decision making regarding surgery.

Entities:  

Keywords:  18F-FDG-PET/CT; Renal cell carcinoma; SUVmax; hybrid imaging; prognosis

Mesh:

Substances:

Year:  2013        PMID: 23749925

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients.

Authors:  Laura Evangelista; Fabio Zattoni; Pierpaolo Alongi
Journal:  Ann Transl Med       Date:  2019-07

2.  Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT.

Authors:  Rei Onishi; Masanori Noguchi; Hayato Kaida; Fukuko Moriya; Katsuaki Chikui; Seiji Kurata; Akihiko Kawahara; Masayoshi Kage; Masatoshi Ishibashi; Kei Matsuoka
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

Review 3.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

Review 4.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

5.  Efficacy of Pre-operative 18F-FDG PET/CT in Prognostic Prediction in Patients With Renal Cell Carcinoma.

Authors:  Masafumi Toguchi; Kousei Ishigami; Masato Goya; Seiichi Saito; Sadayuki Murayama; Akihiro Nishie
Journal:  Cancer Diagn Progn       Date:  2022-03-03

6.  Giant Polycystic Papillary Renal Cell Carcinoma: A Case Report and Literature Review.

Authors:  Zhongming Huang; Hai Wang; Zhigang Ji
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

7.  Primary kidney parenchyma squamous cell carcinoma mimicking xanthogranulomatous pyelonephritis: A case report.

Authors:  Zhao Wang; Bin Yan; Yong-Bao Wei; N A Hu; Qin Shen; Duo Li; Jin-Rui Yang; Xin Yang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

Review 8.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

9.  Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.

Authors:  Miwako Takahashi; Haruki Kume; Keitaro Koyama; Tohru Nakagawa; Tetsuya Fujimura; Teppei Morikawa; Masashi Fukayama; Yukio Homma; Kuni Ohtomo; Toshimitsu Momose
Journal:  Clin Nucl Med       Date:  2015-12       Impact factor: 7.794

10.  FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.

Authors:  Noboru Nakaigawa; Keiichi Kondo; Ukihide Tateishi; Ryogo Minamimoto; Tomohiro Kaneta; Kazuhiro Namura; Daiki Ueno; Kazuki Kobayashi; Takeshi Kishida; Ichiro Ikeda; Hisashi Hasumi; Kazuhide Makiyama; Yoshinobu Kubota; Tomio Inoue; Masahiro Yao
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.